APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microarray-based Non-Invasive Prenatal Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Microarray-based Non-Invasive Prenatal Testing Market Analysis and Forecast 2026-2032

3 May 2026204 pages

Choose your research edition.

Industry ResearchMicroarray-based Non-Invasive Prenatal Testing Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Microarray-based Non-Invasive Prenatal Testing Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Microarray-based Non-Invasive Prenatal Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microarray-based Non-Invasive Prenatal Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Microarray-based Non-Invasive Prenatal Testing Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Microarray-based Non-Invasive Prenatal Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Microarray-based Non-Invasive Prenatal Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Microarray-based Non-Invasive Prenatal Testing include Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, Laboratory Corporation of America, Myriad Genetics, Natera and PerkinElmer Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Microarray-based Non-Invasive Prenatal Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microarray-based Non-Invasive Prenatal Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Microarray-based Non-Invasive Prenatal Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microarray-based Non-Invasive Prenatal Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microarray-based Non-Invasive Prenatal Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microarray-based Non-Invasive Prenatal Testing revenue, projected growth trends, production technology, application and end-user industry.

Microarray-based Non-Invasive Prenatal Testing Segment by Company

Agilent Technologies

Ariosa Diagnostics (Roche)

BGI Group

Eurofins LifeCodexx GmbH

Illumina

Laboratory Corporation of America

Myriad Genetics

Natera

PerkinElmer Inc

Quest Diagnostics

Sequenom

Microarray-based Non-Invasive Prenatal Testing Segment by Type

Trisomy Detection

Microdeletion Syndromes

Other

Microarray-based Non-Invasive Prenatal Testing Segment by Application

Hospitals & Clinics

Independent Laboratories

Microarray-based Non-Invasive Prenatal Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microarray-based Non-Invasive Prenatal Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microarray-based Non-Invasive Prenatal Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microarray-based Non-Invasive Prenatal Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Microarray-based Non-Invasive Prenatal Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Microarray-based Non-Invasive Prenatal Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microarray-based Non-Invasive Prenatal Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microarray-based Non-Invasive Prenatal Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Trisomy Detection Major Player Table 3. Microdeletion Syndromes Major Player Table 4. Other Major Player Table 5. Global Microarray-based Non-Invasive Prenatal Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals & Clinics Major Player Table 7. Independent Laboratories Major Player Table 8. Microarray-based Non-Invasive Prenatal Testing Industry Trends Table 9. Microarray-based Non-Invasive Prenatal Testing Industry Drivers Table 10. Microarray-based Non-Invasive Prenatal Testing Industry Opportunities and Challenges Table 11. Microarray-based Non-Invasive Prenatal Testing Industry Restraints Table 12. Global Microarray-based Non-Invasive Prenatal Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Microarray-based Non-Invasive Prenatal Testing Market Share by Region (2021-2026) Table 15. Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Microarray-based Non-Invasive Prenatal Testing Market Share by Region (2027-2032) Table 17. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Players (2021-2026) Table 19. Global Microarray-based Non-Invasive Prenatal Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Microarray-based Non-Invasive Prenatal Testing Key Players Headquarters & Area Served Table 21. Global Microarray-based Non-Invasive Prenatal Testing Players, Product Type & Application Table 22. Global Microarray-based Non-Invasive Prenatal Testing Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Microarray-based Non-Invasive Prenatal Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Type (2021-2026) Table 29. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Type (2027-2032) Table 30. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Application (2021-2026) Table 34. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Application (2027-2032) Table 35. Agilent Technologies Company Information Table 36. Agilent Technologies Business Overview Table 37. Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 39. Agilent Technologies Recent Development Table 40. Ariosa Diagnostics (Roche) Company Information Table 41. Ariosa Diagnostics (Roche) Business Overview Table 42. Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 44. Ariosa Diagnostics (Roche) Recent Development Table 45. BGI Group Company Information Table 46. BGI Group Business Overview Table 47. BGI Group Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. BGI Group Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 49. BGI Group Recent Development Table 50. Eurofins LifeCodexx GmbH Company Information Table 51. Eurofins LifeCodexx GmbH Business Overview Table 52. Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 54. Eurofins LifeCodexx GmbH Recent Development Table 55. Illumina Company Information Table 56. Illumina Business Overview Table 57. Illumina Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Illumina Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 59. Illumina Recent Development Table 60. Laboratory Corporation of America Company Information Table 61. Laboratory Corporation of America Business Overview Table 62. Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 64. Laboratory Corporation of America Recent Development Table 65. Myriad Genetics Company Information Table 66. Myriad Genetics Business Overview Table 67. Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 69. Myriad Genetics Recent Development Table 70. Natera Company Information Table 71. Natera Business Overview Table 72. Natera Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Natera Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 74. Natera Recent Development Table 75. PerkinElmer Inc Company Information Table 76. PerkinElmer Inc Business Overview Table 77. PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 79. PerkinElmer Inc Recent Development Table 80. Quest Diagnostics Company Information Table 81. Quest Diagnostics Business Overview Table 82. Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 84. Quest Diagnostics Recent Development Table 85. Sequenom Company Information Table 86. Sequenom Business Overview Table 87. Sequenom Microarray-based Non-Invasive Prenatal Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Sequenom Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 89. Sequenom Recent Development Table 90. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 91. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 92. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 93. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 94. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (US$ Million) & (2027-2032) Table 97. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 98. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 99. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 100. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 101. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026) & (US$ Million) Table 103. Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (US$ Million) & (2027-2032) Table 104. China Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 105. China Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 106. China Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 107. China Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 108. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 109. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 110. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 111. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Region (US$ Million) & (2021-2026) Table 114. Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Region (US$ Million) & (2027-2032) Table 115. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026) & (US$ Million) Table 116. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032) & (US$ Million) Table 117. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026) & (US$ Million) Table 118. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032) & (US$ Million) Table 119. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026) & (US$ Million) Table 121. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (US$ Million) & (2027-2032) Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Microarray-based Non-Invasive Prenatal Testing Image Figure 2. Global Microarray-based Non-Invasive Prenatal Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microarray-based Non-Invasive Prenatal Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Trisomy Detection Image Figure 5. Microdeletion Syndromes Image Figure 6. Other Image Figure 7. Global Microarray-based Non-Invasive Prenatal Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Microarray-based Non-Invasive Prenatal Testing Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals & Clinics Image Figure 10. Independent Laboratories Image Figure 11. Global Microarray-based Non-Invasive Prenatal Testing Market Size (US$ Million) & (2021-2032) Figure 12. Global Microarray-based Non-Invasive Prenatal Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Microarray-based Non-Invasive Prenatal Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Microarray-based Non-Invasive Prenatal Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Type (2021-2032) Figure 19. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Application (2021-2032) Figure 22. North America Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032) Figure 24. North America Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032) Figure 25. North America Microarray-based Non-Invasive Prenatal Testing Revenue Share by Country (2021-2032) Figure 26. United States Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032) Figure 31. Europe Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032) Figure 32. Europe Microarray-based Non-Invasive Prenatal Testing Revenue Share by Country (2021-2032) Figure 33. Germany Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032) Figure 43. China Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032) Figure 44. Asia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032) Figure 46. Asia Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032) Figure 47. Asia Microarray-based Non-Invasive Prenatal Testing Revenue Share by Region (2021-2032) Figure 48. Japan Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032) Figure 56. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032) Figure 57. SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue Share by Country (2021-2032) Figure 58. Brazil Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Microarray-based Non-Invasive Prenatal Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Trisomy Detection
  • Microdeletion Syndromes
  • Other
Applications
  • Hospitals & Clinics
  • Independent Laboratories
Companies covered
  • Agilent Technologies
  • Ariosa Diagnostics (Roche)
  • BGI Group
  • Eurofins LifeCodexx GmbH
  • Illumina
  • Laboratory Corporation of America
  • Myriad Genetics
  • Natera
  • PerkinElmer Inc
  • Quest Diagnostics
  • Sequenom

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Microarray-based Non-Invasive Prenatal Testing Market by Type
  3. 1.2.1 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Trisomy Detection
  5. 1.2.3 Microdeletion Syndromes
  6. 1.2.4 Other
  7. 1.3 Microarray-based Non-Invasive Prenatal Testing Market by Application
  8. 1.3.1 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals & Clinics
  10. 1.3.3 Independent Laboratories
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Microarray-based Non-Invasive Prenatal Testing Market Dynamics
  1. 2.1 Microarray-based Non-Invasive Prenatal Testing Industry Trends
  2. 2.2 Microarray-based Non-Invasive Prenatal Testing Industry Drivers
  3. 2.3 Microarray-based Non-Invasive Prenatal Testing Industry Opportunities and Challenges
  4. 2.4 Microarray-based Non-Invasive Prenatal Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Microarray-based Non-Invasive Prenatal Testing Market Perspective (2021-2032)
  2. 3.2 Global Microarray-based Non-Invasive Prenatal Testing Growth Trends by Region
  3. 3.2.1 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Microarray-based Non-Invasive Prenatal Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Players
  2. 4.1.1 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Microarray-based Non-Invasive Prenatal Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Microarray-based Non-Invasive Prenatal Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Microarray-based Non-Invasive Prenatal Testing Key Players Headquarters & Area Served
  7. 4.4 Global Microarray-based Non-Invasive Prenatal Testing Players, Product Type & Application
  8. 4.5 Global Microarray-based Non-Invasive Prenatal Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Microarray-based Non-Invasive Prenatal Testing Market CR5 and HHI
  11. 4.6.3 2025 Microarray-based Non-Invasive Prenatal Testing Tier 1, Tier 2, and Tier 3
5 Microarray-based Non-Invasive Prenatal Testing Market Size by Type
  1. 5.1 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 5.3 Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Type (2021-2032)
6 Microarray-based Non-Invasive Prenatal Testing Market Size by Application
  1. 6.1 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  3. 6.3 Global Microarray-based Non-Invasive Prenatal Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Agilent Technologies
  2. 7.1.1 Agilent Technologies Company Information
  3. 7.1.2 Agilent Technologies Business Overview
  4. 7.1.3 Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  6. 7.1.5 Agilent Technologies Recent Developments
  7. 7.2 Ariosa Diagnostics (Roche)
  8. 7.2.1 Ariosa Diagnostics (Roche) Company Information
  9. 7.2.2 Ariosa Diagnostics (Roche) Business Overview
  10. 7.2.3 Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  12. 7.2.5 Ariosa Diagnostics (Roche) Recent Developments
  13. 7.3 BGI Group
  14. 7.3.1 BGI Group Company Information
  15. 7.3.2 BGI Group Business Overview
  16. 7.3.3 BGI Group Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 BGI Group Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  18. 7.3.5 BGI Group Recent Developments
  19. 7.4 Eurofins LifeCodexx GmbH
  20. 7.4.1 Eurofins LifeCodexx GmbH Company Information
  21. 7.4.2 Eurofins LifeCodexx GmbH Business Overview
  22. 7.4.3 Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  24. 7.4.5 Eurofins LifeCodexx GmbH Recent Developments
  25. 7.5 Illumina
  26. 7.5.1 Illumina Company Information
  27. 7.5.2 Illumina Business Overview
  28. 7.5.3 Illumina Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Illumina Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  30. 7.5.5 Illumina Recent Developments
  31. 7.6 Laboratory Corporation of America
  32. 7.6.1 Laboratory Corporation of America Company Information
  33. 7.6.2 Laboratory Corporation of America Business Overview
  34. 7.6.3 Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  36. 7.6.5 Laboratory Corporation of America Recent Developments
  37. 7.7 Myriad Genetics
  38. 7.7.1 Myriad Genetics Company Information
  39. 7.7.2 Myriad Genetics Business Overview
  40. 7.7.3 Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  42. 7.7.5 Myriad Genetics Recent Developments
  43. 7.8 Natera
  44. 7.8.1 Natera Company Information
  45. 7.8.2 Natera Business Overview
  46. 7.8.3 Natera Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Natera Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  48. 7.8.5 Natera Recent Developments
  49. 7.9 PerkinElmer Inc
  50. 7.9.1 PerkinElmer Inc Company Information
  51. 7.9.2 PerkinElmer Inc Business Overview
  52. 7.9.3 PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  54. 7.9.5 PerkinElmer Inc Recent Developments
  55. 7.10 Quest Diagnostics
  56. 7.10.1 Quest Diagnostics Company Information
  57. 7.10.2 Quest Diagnostics Business Overview
  58. 7.10.3 Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  60. 7.10.5 Quest Diagnostics Recent Developments
  61. 7.11 Sequenom
  62. 7.11.1 Sequenom Company Information
  63. 7.11.2 Sequenom Business Overview
  64. 7.11.3 Sequenom Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sequenom Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  66. 7.11.5 Sequenom Recent Developments
8 North America
  1. 8.1 North America Microarray-based Non-Invasive Prenatal Testing Revenue (2021-2032)
  2. 8.2 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032)
  5. 8.3 North America Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032)
  9. 8.5 North America Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country
  11. 8.6.1 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Microarray-based Non-Invasive Prenatal Testing Revenue (2021-2032)
  2. 9.2 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country
  11. 9.6.1 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Microarray-based Non-Invasive Prenatal Testing Revenue (2021-2032)
  2. 10.2 China Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032)
  5. 10.3 China Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032)
  9. 10.5 China Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Microarray-based Non-Invasive Prenatal Testing Revenue (2021-2032)
  2. 11.2 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Country
  11. 11.6.1 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue (2021-2032)
  2. 12.2 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country
  11. 12.6.1 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Microarray-based Non-Invasive Prenatal Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst